Literature DB >> 678385

The clinical pharmacology of mexiletine.

N P Campbell, J G Kelly, A A Adgey, R G Shanks.   

Abstract

1. Mexiletine was given to 156 patients by intravenous or oral routes of administration. 2. There was great interpatient variation in kinetics and plasma concentrations with both routes of administration. 3. The mean volume of distribution was 6.63 l/kg. The mean plasma elimination haf-life after chronic oral therapy was 11.31 h. 4. Plasma concentrations between 0.75 and 2.00 microgram/ml were usually effective. Within this therapeutic range severe side effects were uncommon. 5. Plasma concentrations within this range were achieved in 72% of patients when doses of 10--14 mg-1 kg-1 day were given orally.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 678385      PMCID: PMC1429421          DOI: 10.1111/j.1365-2125.1978.tb00833.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Oral dosage schedules for mexiletine.

Authors:  A Pottage
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

3.  Measurement of plasma mexiletine concentrations.

Authors:  J G Kelly
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

4.  Absorption, distribution and elimination of mexiletine.

Authors:  L F Prescott; A Pottage; J A Clements
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

5.  St-segment displacement and early hospital discharge in acute myocardial infarction.

Authors:  C Wilson; J F Pantridge
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

6.  Treatment of ventricular arrhythmias with mexiletine (Kö 1173).

Authors:  R G Talbot; J Nimmo; D G Julian; R A Clark; J M Neilson; L F Prescott
Journal:  Lancet       Date:  1973-08-25       Impact factor: 79.321

7.  Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine.

Authors:  J G Kelly; J Nimmo; R Rae; R G Shanks; L F Prescott
Journal:  J Pharm Pharmacol       Date:  1973-07       Impact factor: 3.765

8.  Long-term treatment of ventricular arrhythmias with oral mexiletine.

Authors:  R G Talbot; D G Julian; L F Prescott
Journal:  Am Heart J       Date:  1976-01       Impact factor: 4.749

9.  Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.

Authors:  N P Campbell; J G Kelly; R G Shanks; N C Chaturvedi; J E Strong; J F Pantridge
Journal:  Lancet       Date:  1973-08-25       Impact factor: 79.321

10.  Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction.

Authors:  R W Campbell; M A Dolder; L F Prescott; R G Talbot; A Murray; D G Julian
Journal:  Lancet       Date:  1975-06-07       Impact factor: 79.321

  10 in total
  30 in total

1.  Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes.

Authors:  C Senda; Y Yamaura; K Kobayashi; H Fujii; H Minami; Y Sasaki; T Igarashi; K Chiba
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

Review 2.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Factors influencing the caffeine test for cytochrome P 448-dependent liver function.

Authors:  R Joeres; H Klinker; H Huesler; J Epping; G Hofstetter; D Drost; H Reuss; W Zilly; E Richter
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

4.  Dose independent pharmacokinetics of mexiletine in healthy volunteers.

Authors:  T Pringle; J Fox; J A McNeill; C D Kinney; J Liddle; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

5.  A trial of prophylactic mexiletine in home coronary care.

Authors:  J A Bell; J M Thomas; J R Isaacson; N J Snell; D W Holt
Journal:  Br Heart J       Date:  1982-09

6.  Effect of rifampicin treatment on the kinetics of mexiletine.

Authors:  P J Pentikäinen; I H Koivula; H A Hiltunen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

8.  Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers.

Authors:  Masahiro Otani; Tsuyoshi Fukuda; Masakazu Naohara; Hiromi Maune; Chiaki Senda; Isamu Yamamoto; Junichi Azuma
Journal:  Eur J Clin Pharmacol       Date:  2003-08-23       Impact factor: 2.953

9.  Observations on haemodynamic effects of mexiletine.

Authors:  N P Campbell; S A Zaidi; A A Adgey; G C Patterson; J F Pantridge
Journal:  Br Heart J       Date:  1979-02

10.  The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

Authors:  F Broly; N Vandamme; C Libersa; M Lhermitte
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.